Foghorn Therapeutics

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, when, where, and in what order. By manipulating this system using our unique Gene Traffic Control™ product platform, Foghorn will revolutionize how genes are "turned on" and "off." Unlike gene-editing approaches, this novel perspective will alter what our DNA stores for us and rewrite the fate of millions of patients with diseases. Leveraging the Gene Traffic Control™ product platform, Foghorn Therapeutics is discovering and developing innovative medicines for diseases that target genetic dependencies within the chromatin regulatory system. The company, currently in the preclinical stage, is rapidly advancing over 10 programs across various cancers and beginning to explore treatments for other diseases. Foghorn’s proprietary Gene Traffic Control™ product platform, built on the company’s unique insights into the chromatin regulatory system, enables highly scalable drug discovery and development efforts.